Cost-effectiveness of rotavirus vaccination in peru

Journal of Infectious Diseases

Volumn 200, Issue SUPPL. 1, 2009, Pages

  Clark, Andrew D ^a   Walker, Damian G ^a,b   Rocio Mosqueira, N ^c   Penny, Mary E ^c   Lanata, Claudio F ^c   Fox Rushby, Julia ^a,d   Sanderson, Colin F B ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSIDAD PERUANA DE CIENCIAS APLICADAS   (Peru)

^d BRUNEL UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; INFLUENZA VACCINE; ROTAVIRUS VACCINE;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIPHTHERIA; DISABILITY SEVERITY; DOSE TIME EFFECT RELATION; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HOSPITALIZATION; INFLUENZA; MORTALITY; PERTUSSIS; PERU; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; STATISTICAL MODEL; TETANUS; VACCINATION; VIRUS INFECTION;

CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; HUMANS; INFANT; PERU; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINATION;

EID: 72849135140     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/605043     Document Type: Article

References (40)

1. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23-33. (Pubitemid 43048948) (Pubitemid 43048948)
2. Parashar UD, Glass RI. Progress toward rotavirus vaccines. Science 2006; 312:851.
3. World Health Organization. Rotavirus vaccines. Wkly Epidemiol Rec 2007; 82:285-295
4. GlaxoSmithKline. Rotarix product information. Available at: http://www.gsk.com.au/resources.ashx/vaccineproductschilddataproinfo/116/ FileName/32AE8B6050D22D6F9145C3F882B3238B/PI-otarix.pdf. Accessed 8 April 2008.
5. Centers for Disease Control and Prevention. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2006; 55:1-13.
6. Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat.World population prospects: the 2006 revision and world urbanization prospects. Available at: http://esa.un.org/unpp. Accessed 3 March 2008.
7. Demographic and Health Surveys. 2000. Programa DHS/Macro International. Available at: http://www.measuredhs.com. Accessed 7 January 2008.
8. Ehrenkranz P, Lanata CF, Penny ME, Salazar-Lindo E, Glass RI. Rotavirus diarrhoea disease burden in Peru: the need for a rotavirus vaccine and its potential cost savings. Rev Panam Salud Publica 2001; 10:240-248 (Pubitemid 33064131) (Pubitemid 33064131)
9. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990; 22:259-267
10. Salinas B, Perez-Schael I, Linhares AC, et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomised, placebo-controlled trial in Latin American infants. Pediatr Infect Dis J 2005; 24:807-816 (Pubitemid 41324890) (Pubitemid 41324890)
11. Linhares AC, Bresee JS. Rotavirus vaccines and vaccination in Latin America. Rev Panam Salud Publica 2000; 8:305-331
12. Murray CJL, Lopez AD. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge: Harvard University Press, 1996.
13. Ladabaum U. Safety, efficacy and costs of pharmacotherapy for functional gastrointestinal disorders: the case of alosetron and its implications. Aliment Pharmacol Ther 2003; 17:1021-1030 (Pubitemid 36560802) (Pubitemid 36560802)
14. Pan America Health Organization. Health in the Americas, 2007.Vol. II-Countries. Available at: http://www.paho.org/HIA/archivosvol2/paisesing/ Peru%20English.pdf. Accesed 15 September 2009
15. Pan American Health Organization Health Analysis and Statistics Unit. Regional core health data initiative; technical health information system. Washington DC, 2007. Available at: http://www.paho.org/English/SHA/coredata/ tabulator/newsqlTabulador.asp. Accessed 5 April 2008.
16. Morris SS, Black RE, Tomaskovic L. Predicting the distribution of under-five deaths by cause in countries without adequate vital registration systems. Int J Epidemiol 2003; 32:1041-1051 (Pubitemid 38072693) (Pubitemid 38072693)
17. World Health Organization/CHD Immunisation-Linked Vitamin A Supplementation Study Group. Randomised trial to assess benefits and safety of vitamin A supplementation linked to immunisation in early infancy. Lancet 1998; 352:1257-1263
18. Greenburg BL, Sack RB, Salazar-Lindo E, et al. Measles-associated diarrhoea in hospitalised children in Lima, Peru: pathogenic agents and impact on growth. J Infect Dis 1991; 163:495-502.
19. Figueroa-Quintanilla D, Salazar-Lindo E, Sack RB, et al. A controlled trial of bismuth subsalicylate in infants with acute watery diarrhoeal disease. N Engl J Med 1993; 328:1653-1658 (Pubitemid 23157346) (Pubitemid 23157346)
20. Cama RI, Parashar UD, Taylor DN, et al. Enteropathogens and other factors associated with severe disease in children with acute watery diarrhoea in Lima, Peru. J Infect Dis 1999; 179:1139-1144
21. World Health Organization. Global and national estimates of deaths under age five attributable to rotavirus infection: 2004. Available at: http://www.who.int/immunization-monitoring/burden/rotavirus-stimates/en/. Accessed 20 March 2008.
22. Rheingans RD, Constenla D, Antil L, Innis BL, Breuer T. Economic and health burden of rotavirus gastroenteritis for the 2003 birth cohort in eight Latin American and Caribbean countries. Rev Panam Salud Publica 2007; 21:192-204. (Pubitemid 47147595)
23. Rheingans RD, Antil L, Podewils LJ, Bresse JS, Parashar UD. Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries. J Infect Dis 2009; 200(Suppl 1):S16-27 (in this supplement).
24. World Development Indicators Online. Available at: http://www.worldbank. org/data/onlinedatabases/onlinedatabases.html. Accessed 14 August 2008.
25. OANDA, the Currency Site. Available at: http://www.oanda.com. Accessed 4 March 2008.
26. World Health Organization/United Nations Childrens Fund. Immunization surveillance, assessment and monitoring. Available at: http://www.who.int/ vaccines/globalsummary/immunization/timeseries/tswucoveragedtp1.htm. Accessed 4 March 2008.
27. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11-22. (Pubitemid 43048947) (Pubitemid 43048947)
28. Linhares AC, Velásquez FR, Pérez-Schael I, et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 2008; 371:1181-1189
29. Lanata CF, Black RE, Del Aguila R, et al. Protection of Peruvian children against rotavirus diarrhoea of specific serotypes by the RIT 4237 attenuated bovine rotavirus vaccine. J Infect Dis 1989; 159:452-459 (Pubitemid 19065891)
30. Lanata CF, Midthum K, Black RE, et al. Safety, immunogenicity and protective efficacy of one or three doses of the Rhesus tetravalent rotavirus vaccine in infants from Lima, Peru. J Infect Dis 1996; 174: 268-275 (Pubitemid 26251410)
31. Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007; 370:1757-1763 (Pubitemid 350137490) (Pubitemid 350137490)
32. Pan American Health Organisation. Immunization Newsletter. Vol.XXX. No.1. 2008. Available at: http://www.paho.org/english/ad/fch/im/sne3001.pdf. Accessed 21 September 2009.
33. Rheingans RD, Constenla D, Antil L, Innis BL, Breuer T. Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries. Rev Panam Salud Publica 2007; 21:205-216 (Pubitemid 47147596) (Pubitemid 47147596)
34. World Health Organization. CHOICE (Choosing Interventions that are Cost-Effective). Available at: http://www.who.int/choice/costs/CER-thresholds/ en/index.html. Accessed 14 August 2008.
35. World Bank. GNI per capita 2006, Atlas method and PPP. Available at: http://siteresources.worldbank.org/DATASTATISTICS/Resources/GNIPC.pdf. Accessed 3 March 2008.
36. Constenla D, Gomez E, de la Hoz F, et al. The burden of pneumococcal disease and cost-effectiveness of a pneumococcal vaccine in Latin America and the Caribbean. Sabin Vaccine Institute 2007; 1:129.
37. Weijer C, Lanata CF. Ethical considerations in the conduct of vaccine trials in developing countries. In: Levine MM, Kaper JB, Rappuoli R, Liu MA, Good MF, eds. New generation vaccines. 3rd ed. New York: Marcel Dekker, 2004:49-55.
38. Pérez-Schael I, Guntiñas M, Pérez M, et al. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N Engl J Med 1997; 337:1181-1187 (Pubitemid 27454449) (Pubitemid 27454449)
39. World Development Indicators database, World Bank, 15 September 2009. Gross national income per capita 2008, Atlas method and PPP. Available at: http://siteresources.worldbank.org/DATASTATISTICS/Resources/GNIPC.pdf. Accessed 21 September 2009.
40. World Health Organization. Global Advisory Committee on Vaccine Safety, 1-2 December 2005. Available at: http://www.who.int/vaccine-safety/reports/Dec- 2005/en/index.html. Accessed 21 September 2009.